ArticleScientific reports2025
Bioinformatics analysis of Rho-signal transduction genes in postmenopausal osteoporosis and periodontitis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MYC-SEPT11 Axis Promotes osteoblast differentiation and bone formation via PI3K/AKT and RhoA/ROCK signaling pathways.Functional & integrative genomics · 2026Article
- Targeting innate immunity to modulate bone metabolism: a novel strategy for osteoporosis treatment.Frontiers in aging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Postmenopausal osteoporosis (PMOP) increases the risk of periodontitis (PD), yet the shared mechanisms remain unclear. Rho-signal transduction genes may play a role due to their involvement in bone remodeling. This study aimed to explore Rho-related genes as potential biomarkers linking PMOP and PD. Public transcriptomic datasets of PMOP and PD were analyzed. After PCA-based outlier removal, differentially expressed genes were identified using limma, followed by intersection analysis, KEGG enrichment, PPI network construction, and Rho pathway screening. Machine learning (Lasso, SVM-RFE) and Wilcoxon tests identified CTNNAL1 and MERTK as candidate biomarkers. GSEA, ssGSEA, and immune infiltration analyses were performed, along with construction of lncRNA/circRNA-miRNA-mRNA regulatory networks. Subcellular localization, chromosomal mapping, disease association, and molecular docking analyses were also conducted. An ovariectomy plus periodontitis (OP+PD) mouse model was used for in vivo validation. CTNNAL1 and MERTK were consistently dysregulated in both PMOP and PD datasets. They were enriched in MYC-targets-V1, allograft rejection, heme metabolism, and oxidative phosphorylation. Immune analysis revealed altered levels of CD56^bright NK cells and immature dendritic cells. Regulatory networks implicated lncRNAs such as XIST, GAS5, and NEAT1. Molecular docking indicated interactions with pinosylvin and glycitein. In vivo validation confirmed significant changes in CTNNAL1 and MERTK expression and increased bone loss and inflammation in OP+PD mice. CTNNAL1 and MERTK were identified as potential Rho-associated biomarkers showing consistent dysregulation in both PMOP and PD datasets. These biomarkers may serve as risk indicators or therapeutic candidates, warranting further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.